The TOGETHER-PsA conference abstract reports a higher 52-week arthritis response rate with tirzepatide plus ixekizumab than with ixekizumab alone. It studied adults with active psoriatic arthritis and obesity or qualifying overweight. It did not test tirzepatide alone against placebo. 2 3

What is the current news?

Lilly highlighted the one-year findings on November 5, 2026 ahead of ACR Convergence in Orlando. The oral presentation is scheduled for November 11. The public abstract is available, but this report does not claim to have reviewed a presentation that has not yet occurred. 1

What did the trial compare?

The registry describes a randomized, open-label trial: participants received ixekizumab with or without tirzepatide. Eligibility required active psoriatic arthritis and either obesity or overweight with at least one specified weight-related condition. The comparison therefore concerns adding tirzepatide to an existing arthritis medicine in a defined population. 3

The registered primary endpoint was measured at week 36 and required both ACR50 and at least 10% weight reduction. The current conference report concerns prespecified week-52 outcomes. Calling every one-year result the primary endpoint would blur that distinction. 2 3

What does ACR50 measure?

ACR50 is a composite response threshold. The registry specifies improvement of at least 50% in tender and swollen joint counts, plus improvement in at least three additional assessments. Those assessments include pain, patient and physician disease-activity ratings, physical function and an inflammatory marker. 3

It does not mean half the participants recovered, nor does it mean every symptom improved by exactly half. It identifies the proportion meeting a defined set of response criteria. Keeping the definition beside the result makes the percentage easier to interpret. 3

What happened at 52 weeks?

The abstract reports ACR50 in 43.7% of the combination group versus 15.7% with ixekizumab alone: a 28.0 percentage-point difference. It also reports improvements in other disease-activity and metabolic measures. These are study-group results, not a prediction for an individual patient. 2

What limits the interpretation?

The trial was open label. The abstract states that the week-52 analyses had no multiplicity control, meaning the reported p-values were not adjusted for the multiple comparisons. It also reports that 71.6% completed study treatment. Both analysis choices and incomplete treatment participation matter when interpreting the findings. 2

Investigators describe adverse events as consistent with the medicines’ established profiles and adverse-event discontinuations as comparable between groups. That is a summary of observed trial safety, not proof of no risk. The accessible abstract does not provide the same detail as a full safety dataset. 2

Does this establish tirzepatide as an arthritis medicine?

The study cannot isolate the effect of tirzepatide without ixekizumab because it did not include a tirzepatide-only arm. Nor does it establish that the observed difference comes entirely from direct anti-inflammatory activity rather than weight change or other factors. Those are additional research questions. 3

Lilly identifies Taltz as an IL-17A-targeting antibody used for active psoriatic arthritis, while Zepbound is its tirzepatide obesity medicine. The combination findings do not establish a new standalone arthritis indication for tirzepatide. They also concern a different disease and trial from retatrutide’s knee-osteoarthritis research. 1

Scope for European readers

This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.